ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
October 25, 2023 06:50 ET
|
ZyVersa Therapeutics
Obesity exacerbates scarring of the heart through ASC-driven inflammasome activation in the heart leading to damaging inflammation.
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
October 18, 2023 07:05 ET
|
ZyVersa Therapeutics
Inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease.
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
October 16, 2023 14:40 ET
|
BioAegis Therapeutics
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
Addressing Unmet Needs: The SLE Market Grows as Research and Development Flourish
October 06, 2023 06:08 ET
|
Research and Markets
Dublin, Oct. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, & Region): Insights & Forecast with...
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
September 27, 2023 07:07 ET
|
ZyVersa Therapeutics
Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa is advancing a dynamic pipeline of drug candidates with...
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
September 11, 2023 07:00 ET
|
InflaRx N.V.
SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: Safety and tolerability with no signals of concern over entire dose rangePharmacokinetics (PK): favorable...
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
July 26, 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
July 13, 2023 08:00 ET
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
May 25, 2023 09:07 ET
|
ZyVersa Therapeutics
Juvenile idiopathic arthritis (“JIA”), a complex autoimmune inflammatory disorder, is the most common childhood chronic rheumatic diseaseThis is the first report documenting inflammasome activation in...
Allergy Conjunctivitis Global Market Report 2023: Rise in Air Pollutants and Chemicals Drives Growth
May 16, 2023 04:43 ET
|
Research and Markets
Dublin, May 16, 2023 (GLOBE NEWSWIRE) -- The "Allergy Conjunctivitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global allergy conjunctivitis market...